NCT03358030View on ClinicalTrials.gov

A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis

PHASE2CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

December 26, 2017

Primary Completion Date

July 10, 2019

Study Completion Date

July 10, 2019

Conditions
End-stage Renal Disease (ESRD)
Interventions
DRUG

ISIS 416858

Subcutaneous injection

DRUG

Placebo

Subcutaneous injection

Trial Locations (2)

15706

Ionis Investigative Site, Santiago de Compostela

28805

Ionis Investigative Site, Alcalá de Henares

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Ionis Pharmaceuticals, Inc.

INDUSTRY